CYCanan Yasar

Canan Yasar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Canan Yasar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Surgical elimination of inflammatory fibrous hyperplasia associated with combination syndrome: a two-year follow-up case report

    by Cansu Can Yasar, Kamar Albaba, Ganime Coban

    Inflammatory fibrous hyperplasia (IFH), also known as epulis fissuratum, is a reactive mucosal overgrowth caused by chronic denture-related irritation. This report describes a 58-year-old woman with a painful fibrous enlargement in the maxillary anterior vestibule associated with the long-term use of an ill-fitting complete denture. The lesion was excised using a scalpel, with simultaneous vestibuloplasty performed to increase vestibular depth and improve denture stability. Histopathological examination confirmed the diagnosis of IFH. Following soft tissue healing, a new maxillary complete denture was fabricated, and border adjustments were performed during follow-up. At the two-year follow-up, the surgical site remained stable, with preserved vestibular depth and no evidence of recurrence. This case highlights the importance of combined surgical and prosthetic management in achieving long-term tissue stability.

  • Annexin A1 levels in polycystic ovary syndrome: impact of professional mechanical plaque removal

    by Cansu Can Yasar, Seda Ates, Turgut Aksoy, Aysegul Yabaci Tak, Esra Demir, Sadiye Gunpinar

    Objective This study aimed to investigate the local inflammatory profile in women with polycystic ovary syndrome (PCOS) by assessing interleukin (IL)-6, IL-10, and annexin A1 (ANXA1) levels in saliva and gingival crevicular fluid (GCF), and to compare the clinical and biochemical responses to proffessional mechanical plaque removal (PMPR) between women with PCOS and systemically healthy individuals. Methods Eighty women were allocated into four groups: (1) PCOS-healthy periodontium (PCOSH), (2) PCOS-gingivitis (PCOSG), (3) systemically healthy-gingivitis (SG), (4) systemically and periodontally healthy (SH). Clinical periodontal parameters and saliva/GCF samples were collected at baseline and 6 weeks after PMPR. IL-6, IL-10, and ANXA1 levels were measured by ELISA. Data were analyzed using one-way ANOVA, Kruskal-Wallis tests, and multiple linear regression. Results Both gingivitis groups showed comparable clinical improvements and significant reductions in salivary IL-6 levels and the IL-6/IL-10 ratio following PMPR, independent of PCOS status. Notably, GCF ANXA1 levels increased in PCOSG but decreased in SG. In the PCOSG group, baseline levels of estradiol and follicle-stimulating hormone were significant predictors of changes in GCF ANXA1, as indicated by multiple regression analysis. Conclusion PMPR may lead to similar clinical and local biochemical outcomes in patients with gingivitis, regardless of PCOS status. ANXA1 may have a specific role in modulating gingival inflammation in women with PCOS. Clinical relevance This study highlights the importance of managing gingivitis in women with PCOS, suggesting that periodontal treatment may result in comparable improvements. Additionally, the findings suggest a potential modulatory role for ANXA1 in the periodontal inflammatory response associated with PCOS.


  • Open Access

    Failure of Direct Oral Anticoagulants in Three Patients with Antiphospholipid Antibody Syndrome

    by Firdevs Ulutas, Ugur Karasu, Veli Cobankara, Serdar Kaymaz, Canan Yasar

    Antiphospholipid antibody syndrome is a clinical condition that is characterized by recurrent venous and/or arterial thrombosis, and/or pregnancy morbidity in patients who have positive antiphospholipid antibodies. Clinicians firstly aim to prevent recurrent thrombosis by long-term anticoagulation in these patients. Warfarin is the mainstay drug that is most commonly used in thrombotic antiphospholipid antibody syndrome. It’s narrow therapeutic window requires close regular monitoring of the International Normalized Ratio (INR), which is inconvenient and costly. In the past decade direct oral anticoagulants have been characterized. Today we do not know whether direct oral anticoagulants are safe and effective in comparison with warfarin in patients with antiphospholipid antibody syndrome. We report herein three patients with failure of thrombotic prevention during treatment with rivaroxaban and dabigatran.

  • OP-292 SURGICAL TREATMENT PRINCIPLES OF AORTIC COARCTATION IN CHILDREN AND ADULTS

    by H.T. Keçeligil, S.M. Yucel, C. Yasar, M.K. Demirag, F. Kolbakir